P. Morice, A. Leary, C. Creutzberg, N. Abu-Rustum, E. Darai, Endometrial cancer, The Lancet 387(10023) (2016) 1094-1108.
 R. Angioli, F. Plotti, S. Capriglione, R. Montera, P. Damiani, R. Ricciardi, A. Aloisi, D. Luvero, E.V. Cafa, N. Dugo, M. Angelucci, P. Benedetti-Panici, The role of novel biomarker HE4 in endometrial cancer: a case control prospective study, Tumour Biol 34(1) (2013) 571-6.
 J.I. Sorosky, Endometrial cancer, Obstet Gynecol 120(2 Pt 1) (2012) 383-97.
 K.M. Doll, A.N. Winn, Assessing endometrial cancer risk among US women: long-term trends using hysterectomy-adjusted analysis, Am J Obstet Gynecol 221(4) (2019) 318 e1-318 e9.
. W. Chen, R. Zheng, P.D. Baade, S. Zhang, H. Zeng, F. Bray, A. Jemal, X.Q. Yu, J. He, Cancer statistics in China, 2015, CA Cancer J Clin 66(2) (2016) 115-32.
 R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA Cancer J Clin 70(1) (2020) 7-30
 R.G. Moore, C.M. Miller, A.K. Brown, K. Robison, M. Steinhoff, G. Lambert-Messerlian, Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus, Int J Gynecol Cancer 21(7) (2011) 1185-90.
 K. Abbink, P.L. Zusterzeel, A.J. Geurts-Moespot, A.E.V. Herwaarden, J.M. Pijnenborg, F.C. Sweep, L.F. Massuger, HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients, Tumour Biol 40(2) (2018) 1010428318757103.
 J. Bian, X. Sun, B. Li, L. Ming, Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer, Technol Cancer Res Treat 16(4) (2017) 435-439.
 J.M. Escudero, J.M. Auge, X. Filella, A. Torne, J. Pahisa, R. Molina, Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases, Clin Chem 57(11) (2011) 1534-44.
 M. Li, L. Zhao, D. Shen, X. Li, J. Wang, L. Wei, Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma, Chin Med J (Engl) 127(8) (2014) 1459-63.
 A.C. Staff, J. Trovik, A.G. Eriksson, E. Wik, K.C. Wollert, T. Kempf, H.B. Salvesen, Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer, Clin Cancer Res 17(14) (2011) 4825-33.
 T. Kurihara, H. Mizunuma, M. Obara, K. Andoh, Y. Ibuki, T. Nishimura, Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma, Gynecol Oncol 69(3) (1998) 192-6.
 E. Baser, T. Gungor, C. Togrul, O. Turkoglu, S. Celen, Preoperative prediction of poor prognostic parameters and adjuvant treatment in women with pure endometrioid type endometrial cancer: what is the significance of tumor markers?, Eur J Gynaecol Oncol 35(5) (2014) 513-8.
 A. Gadducci, S. Cosio, A. Carpi, A. Nicolini, A.R. Genazzani, Serum tumor markers in the management of ovarian, endometrial and cervical cancer, Biomed Pharmacother 58(1) (2004) 24-38.
 T. Kaku, T. Kamura, T. Hirakawa, K. Sakai, S. Amada, H. Kobayashi, H. Nakano, Endometrial carcinoma associated with hyperplasia--immunohistochemical study of angiogenesis and p53 expression, Gynecol Oncol 72(1) (1999) 51-5.
 M. Modarres-Gilani, M. Vaezi, M. Shariat, N. Zamani, R. Nourizadeh, The prognostic role of preoperative serum CA125 levels in patients with advanced endometrial carcinoma, Cancer Biomark 20(2) (2017) 135-141.
 B. Patsner, G.W. Yim, Predictive value of preoperative serum CA-125 levels in patients with uterine cancer: The Asian experience 2000 to 2012, Obstet Gynecol Sci 56(5) (2013) 281-8.
 M. Nikolaou, H.P. Kourea, V. Tzelepi, G. Adonakis, C.D. Scopa, V. Tsapanos, D. Kardamakis, C. Kalofonos, G. Decavalas, The prognostic role of preoperative serum CA 125 levels in patients with endometrial carcinoma, J BUON 19(1) (2014) 198-202.
 K.A. Williams, K.L. Terry, S.S. Tworoger, A.F. Vitonis, L.J. Titus, D.W. Cramer, Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival, PLoS One 9(2) (2014) e88334.
 B. Patsner, W.J. Mann, H. Cohen, M. Loesch, Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma, Am J Obstet Gynecol 158(2) (1988) 399-402.
 E. Bignotti, M. Ragnoli, L. Zanotti, S. Calza, M. Falchetti, S. Lonardi, S. Bergamelli, E. Bandiera, R.A. Tassi, C. Romani, P. Todeschini, F.E. Odicino, F. Facchetti, S. Pecorelli, A. Ravaggi, Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients, Br J Cancer 104(9) (2011) 1418-25.
 K. Abiko, T. Baba, M. Ogawa, Y. Mikami, T. Koyama, M. Mandai, I. Konishi, Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus, Pathol Int 60(1) (2010) 42-7.
 D.J. Brennan, A. Hackethal, A.M. Metcalf, J. Coward, K. Ferguson, M.K. Oehler, M.A. Quinn, M. Janda, Y. Leung, M. Freemantle, A. Group, P.M. Webb, A.B. Spurdle, A. Obermair, Serum HE4 as a prognostic marker in endometrial cancer--a population based study, Gynecol Oncol 132(1) (2014) 159-65.
 M. El-Bahrawy, Alpha-fetoprotein-producing non-germ cell tumours of the female genital tract, Eur J Cancer 46(8) (2010) 1317-22.
 J.S. Su, Y.T. Chen, R.C. Wang, C.Y. Wu, S.W. Lee, T.Y. Lee, Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review, World J Gastroenterol 19(3) (2013) 321-7.
 A. Andren-Sandberg, Molecular biology of gallbladder cancer: potential clinical implications, N Am J Med Sci 4(10) (2012) 435-41.
 P. Letelier, P. Brebi, O. Tapia, J.C. Roa, DNA promoter methylation as a diagnostic and therapeutic biomarker in gallbladder cancer, Clin Epigenetics 4(1) (2012) 11.